论文信息 - Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers - 字舞流文

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

G. Shapiro | R. Prinjha | S. Piha-Paul | P. O'dwyer | O. Barbash | C. French | N. Parr | C. Hann | Yuehui Wu | A. Wyce | A. Dhar | S. Harward | C. Carpenter | Thierry Horner | Gerladine Ferron-Brady | Meg Annan | Anastasia Wyce